A new understanding of the intricate biological steps that lead to the development of Alzheimer’s opens the door to new treatments that could halt the progression of the disease.
“We’ve been looking at Alzheimer’s disease all wrong,” says Prof Lars Ittner, discussing his latest study. “Until now, research has missed the first essential step in the development of Alzheimer’s, which involves tau and its protective effect.”
This startling new discovery is a result of research that Prof Ittner has been conducting since 2010, when he first identified that two proteins – tau and amyloid-beta – together created a toxicity in the brain that lead to Alzheimer’s disease. This work was published in Cell.
To further understand why this toxicity occurred, Prof Ittner recruited his brother, Dr Arne Ittner, a cell biologist, to participate in the study. Together, the brothers worked to understand the complex relationship between tau and amyloid-beta.
This led them to their most recent discovery, which has changed the way they view the development of Alzheimer’s disease altogether. Their study revealed that tau, which has long been thought to contribute to the cell death that leads to Alzheimer’s, actually has a protective effect on the brain in the early stage of disease.
This finding, which was published in the journal Science, overturns previously held ideas of how the disease develops and opens the door to new treatment options that could halt or slow the progression of the AD.
Plaques and tangles
Around 354,000 Australians are living with Alzheimer’s and other dementia-related illnesses. This figure is likely to rise to 900,000 by 2050, unless a treatment is found in the meantime.
There are many theories about what causes Alzheimer’s, but the most well-supported concept involves “plaques” and “tangles”. Plaques are clusters of amyloid-beta, which builds up between nerve cells. And tangles are formed by tau, which accumulates within nerve cells.
The accumulation of these plaques and tangles is associated with degeneration of brain tissue and memory loss. The Ittners’ research has revealed that a crucial step in the process that leads to tangles has been misunderstood.
Initially, it was thought that amyloid-beta prompted a change in tau, causing it to become toxic. However, results from the new study suggest that tau changes itself in order to protect neurons, and that amyloid-beta assaults this protective functionality until it is progressively lost. This is the stage at which toxicity levels cause the destruction of neurons and results in the memory loss and confusion associated with Alzheimer’s disease.
Their study revealed that a third protein, kinase p38γ, aided tau in its efforts to protect against damage. But, as levels of p38γ became depleted in the brain, so too were the protective benefits reduced.
“This is a change in concept,” Prof Ittner explains. “We have completely changed our view on the whole disease process involving this protein, p38γ, which is central to the disease. When other researchers recognise this, it will change their views on the disease process too.”
Crucially, this study has revealed that p38γ is a potential therapeutic target. Using animal model studies, the brothers found that Alzheimer-like symptoms emerged in mice when p38γ was blocked. When they reintroduced the protein, however, the symptoms disappeared.
“This finding has opened the door to possible treatments, given time,” says Lars. “The protein has a relatively clear function,” adds Arne, which he believes makes it a particularly valuable treatment target.
“As the protein is lost during the progression of the disease, you lose the protective function. But there is still remaining protein left, so if you can stimulate that function, we may be able to delay the onset of deficits.
“The development of therapeutics is a whole different area of research, but this will push the boundaries forward,” says Lars.
Associate Professor Tony Roscioli has joined NeuRA as a Senior Research Scientist and Group Leader in Neurogenomics. He is also a Staff Specialist in Clinical Genetics at Sydney Children’s Hospital and is the leader of the SPHERE Genome Connect clinical academic stream. A/Prof Roscioli leads the NHMRC Centre for Research excellence in Neurocognitive Disorders at NeuRA, which endeavours to […]